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Background: Clinicians reported an increasing trend of rapid progression (RP) (AIDS within 3 years of infection)
in Cuba.
Methods:Recently infected patients were prospectively sampled, 52 RP at AIDS diagnosis (AIDS-RP) and 21with-
out AIDS in the same time frame (non-AIDS). 22 patients were sampled at AIDS diagnosis (chronic-AIDS) retro-
spectively assessed as N3 years infected. Clinical, demographic, virological, epidemiological and immunological
datawere collected. Pol and env sequenceswere used for subtyping, transmission cluster analysis, and prediction
of resistance, co-receptor use and evolutionary ﬁtness. Host, immunological and viral predictors of RP were ex-
plored through data mining.
Findings: Subtyping revealed26 subtypeBstrains, 6C, 6CRF18_cpx, 9CRF19_cpx, 29BG-recombinants andother sub-
types/URFs. All patients infected with CRF19 belonged to the AIDS-RP group. Data mining identiﬁed CRF19, oral can-
didiasis and RANTES levels as the strongest predictors of AIDS-RP. CRF19 was more frequently predicted to use the
CXCR4 co-receptor, had higher ﬁtness scores in the protease region, and patients had higher viral load at diagnosis.
Interpretation: CRF19 is a recombinant of subtype D (C-part of Gag, PR, RT and nef), subtype A (N-part of Gag,
Integrase, Env) and subtype G (Vif, Vpr, Vpu and C-part of Env). Since subtypes D and A have been associated with
respectively faster and slower disease progression, our ﬁndings might indicate a ﬁt PR driving high viral load,
which in combination with co-infections may boost RANTES levels and thus CXCR4 use, potentially explaining the
fast progression. We propose that CRF19 is evolutionary very ﬁt and causing rapid progression to AIDS in many
newly infected patients in Cuba.© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Despite a low HIV-1 prevalence, diverse clades are circulating in
Cuba (Thomson and Nájera, 2005) mainly subtypes B, C, G and H, BG
recombinant forms and complex circulating recombinant forms (CRFs)Microbiology and Immunology,
l and Epidemiological Virology,
-M. Vandamme).
y.
. This is an open access article underCRF18_cpx and CRF19_cpx (Thomson and Nájera, 2005; Casado et al.,
2005; Sierra et al., 2007; Delatorre and Bello, 2013). Whereas the BG
recombinants have a Cuban origin, CRF18_cpx and CRF19_cpx seem
African (Thomson and Nájera, 2005; Casado et al., 2005; Sierra et al.,
2007; Delatorre and Bello, 2013), but became epidemic only in Cuba.
This diversity is in contrastwith the almost exclusive subtype B epidem-
ic (94%) in the rest of the Caribbean (Vaughan et al., 2003). From2008 to
2011, 1200 to 1800 individuals have been newly diagnosed with HIV-1
in Cuba each year, of whom 13 to 16% had AIDS at diagnosis, more than
in the previous decade (Abrahantes Rodríguez et al., 2010).
Rapid progression to AIDS (within 3 years after seroconversion
(Casado et al., 2010)) has been associated to virus genetics (Pushkerthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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(Helleberg et al., 2013; Murphy et al., 2013), co-receptor use (Kaleebu
et al., 2007), co-infection (Secor, 2012; Pawlowski et al., 2012; Alemu
et al., 2013; Hernandez and Sherman, 2011), and immune activation
(Liovat et al., 2012; Giorgi et al., 1999; Roberts et al., 2011). Rapid progres-
sion is associated with poorer cellular immune response (Demarest et al.,
2001) and, occasionally, also to poorer HIV-speciﬁc humoral immune re-
sponse (Sapsutthipas et al., 2013; Bártolo et al., 2009). In addition, higher
expression of immunosuppression markers (Lajoie et al., 2009) and spe-
ciﬁc host genetic variants (Casado et al., 2010; Le Clerc et al., 2009;
Limou et al., 2009) is also associated with AIDS rapid progression. Com-
pared to subtype A, subtype D is associated with a higher risk of
progressing to AIDS (Baeten et al., 2007; Kaleebu et al., 2002). Infection
with A/D recombinant viruses resulted in signiﬁcantly faster progression
to AIDS than did infection with pure subtype A (Kiwanuka et al., 2008).
Phenotypic switching from CCR5 to CXCR4-using variants is well-
known to be associated with rapid progression in subtype B
(Esbjörnsson et al., 2010), while recent data report similar fast progres-
sion in patients infected with CXCR4-using variants of other clades (Li
et al., 2014). However, no subtype or CRF has been exclusively associated
with rapid progression.
To investigate this potentially increased proportion of patients with
rapid progression to AIDS over the last decade in Cuba, we set up an
exploratory study evaluating the association of rapid progression with
epidemiological, clinical, viral and immunological parameters, compar-
ing three groups of patients. The ﬁrst two groupswere newly diagnosed
patients with an HIV negative test less than three years earlier recruited
prospectively who within 3 years after seroconversion either were
already diagnosed with AIDS (AIDS-RP) or were still AIDS-free (non-
AIDS) and chronically infectedHIV-1 patientswith AIDS recruited retro-
spectively (chronic-AIDS).
2. Patients and Methods
2.1. Study Population
From November 2007 onwards, adult HIV-1 patients attending the
Institute for Tropical Medicine “Pedro Kourí” (IPK) for medical care
were consecutively recruited when 1) having a negative HIV testTable 1
Patient characteristics at HIV diagnosis for the non-AIDS, chronic-AIDS and AIDS-RP groups. D
number of patients between brackets. Disease progression statistical differenceswere tested us
at p-value b0.05 (displayed in bold). N = number of patients. NS = not signiﬁcant.
Non-AID
Last negative HIV test before HIV diagnosis (months) 22.0 (10.
Log VL at HIV diagnosis (RNA copies/ml plasma) b1.7 (b1
CD4% at HIV diagnosis 27 (19–3
CD4 count at HIV diagnosis (cells per μl blood) 577 (441
Age at HIV diagnosis (years) 29 (22–3
Number of sexual partners in the year before diagnosis 2.0 (1.0–
Acute retroviral syndrome at HIV diagnosis 65.0% (1
Gender (proportion of male) 85.0% (1
Skin color
White 60.0% (1
Black 15.0% (3
Mulatto 25.0% (5
Anal sex (as reported by both males and females of various sexual orientation) 80.0% (1
Always condom use after diagnosis 45.0% (9
Sexual orientation
Heterosexual 20.0% (4
Homosexual 65.0% (1
Bisexual 15.0% (3
Residence in Havana 66.7% (1
Sexual contact with known HIV seropositive 55.0% (1
AIDS deﬁnition criteria CD4 low (b200 cells/mm3 or b14%) –
Waste Syndrome –
Opportunistic infections –
Pneumocystis jirovecii –less than 3 years before HIV-1 diagnosis and 2) being therapy-naive
(Table 1). HIV seroconversion date was the midpoint between last
negative and ﬁrst positive HIV test. AIDS was deﬁned if CD4 count
b200 cells/μl, CD4% b14% or if at least 1 of any 26 enlisted opportunistic
infections and/or cancerswere documented (Rutledge and Boyd, 2008).
Patientswere recruited into the group of a) rapid progressors (AIDS-RP)
when diagnosedwith AIDS within 3 years after seroconversion and had
at least opportunistic infection or previous consecutive (with at least
1 month interval) CD4 counts b350 cells/μl to exclude potential false-
positive AIDS diagnosis due to transient low CD4 counts during acute
HIV-1 infection (Casado et al., 2010); b) non-AIDS patients when still
AIDS-free 3 years after seroconversion (non-AIDS); or c) as chronically
infected AIDS patients (chronic-AIDS) when diagnosed with AIDS dur-
ing the studyperiodmore than 3 years (judged retrospectively) after se-
roconversion. Median year of HIV-1 diagnosis for chronic-AIDS patients
was 2001 (IQR = 1997–2002) and of AIDS deﬁnition it was 2008 (IQR
= 2008–2008) (Supplementary ﬁgure 1A). Recruitment into the study
did not interfere with standard medical care, and patients were treated
according to the prevailingCuban/WHOguidelines. The studywas in ac-
cordancewith theHelsinki Declaration and approved by the ethics com-
mittee of IPK. All participants provided written informed consent.
2.2. Measurement of Immunological Markers and Viral Load
CD4 cell counts were determined by FACScan (Becton Dickinson,
USA), plasma HIV-1 viral loads by NucliSENS (Biomérieux, France), cy-
tokine and chemokine plasma levels by FlowCytomix (eBioscience,
USA): human IL-1b, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12p70, G-CSF,
TNF-α, TNF-β, IFN-α and IFN-γ, MIP-1α, MIP-1β, IP-10, MIG, MCP-1
and RANTES. Neopterin (IBL Inc., Germany), β2-microglobulin
(Immundiagnostik AG, Germany), FasL (IBL Inc., Germany) and sFas
(IBL Inc., Germany) plasma levels were quantiﬁed using ELISA kits.
2.3. HIV Genetic Analyses
Population-based bi-directional Sanger sequencing of pol and env
fragments resulted in on average 1300 NT for pol (HXB2 NT position
2253–3554) and 2078 NT for env (HXB2 NT position 6417–8497)
(Pérez et al., 2013; Van Laethem et al., 2005) (Supplementary Table 1).ata are expressed as median values with interquartile ranges, or as proportion (%) with
ing Kruskal–Wallis or Chi-square test for trend. Statistical tests were considered signiﬁcant
S (N = 21) Chronic-AIDS (N = 22) AIDS-RP (N = 52) p value
5–25.0) (N = 21) 22.0 (12.0–24.0) (N = 22) 14.0 (5.3–23.5) (N = 52) 0.17
.7–3.5) (N = 12) 3.2 (b1.7–3.9) (N = 8) 4.8 (4.1–5.4) (N = 41) b0.0001
5) (N = 20) 24 (19–30) (N = 21) 13 (10–19) (N = 49) b0.0001
–815) (N = 20) 522 (374–782) (N = 22) 276 (152–386) (N = 49) b0.0001
7) (N = 20) 31 (24–35) (N = 22) 34 (26–41) (N = 51) 0.34
4.8) (N = 20) 2.0 (1.0–5.3) (N = 22) 2.0 (1.0–3.0) (N = 51) 0.54
3/20) 50.0% (11/22) 45.1% (23/51) 0.15
7/20) 86.4% (19/22) 74.5% (38/51) 0.24
2/20) 45.5% (10/22) 64.7% (33/51) 0.49
/20) 18.2% (4/22) 23.5% (12/51) 0.40
/20) 36.4% (8/22) 11.8% (6/51) 0.09
6/20) 54.6% (12/22) 50.0% (25/50) 0.031
/20) 45.5% (10/22) 19.6% (10/51) 0.016
/20) 36.4% (8/22) 49.0% (25/51) 0.023
3/20) 45.5% (10/22) 41.2% (21/51) 0.087
/20) 18.2% (4/22) 9.8% (5/51) 0.44
4/21) 71.4% (15/21) 68.0% (34/50) 0.97
1/20) 81.8% (18/22) 54.9% (28/51) 0.60
95.46% (21/22) 98.08% (51/52) 0.52
9.09% (2/22) 9.62% (5/52) 0.94
13.64% (3/22) 25.00% (13/52) 0.28
0.00% (0/22) 13.46% (7/52) 0.071
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comet.retrovirology.lu) (Struck et al., 2010) and REGA version 3 (http://
regatools.med.kuleuven.be/typing/v3/hiv/typingtool/) (De Oliveira et al.,
2005; Pineda-Peña et al., 2013), conﬁrmed with manual phylogenetic
analysis (Pérez et al., 2006). Because of similar breakpoints in the pol re-
gion and lack of breakpoints in the env region, pol and env sequences ini-
tially assigned to CRF20_BG, CRF23_BG or CRF24_BG were aligned with
the pol and env regions from all full genome sequences of these three
CRFs and the full genome subtype reference sequences available in Los
Alamos database (accessed August 2013), then a Maximum Likelihood
(ML) tree was constructed with RaxML (GTR + Γmodel and 1000 boot-
strap replicates) (Stamatakis, 2006). All potential CRF20_BG, CRF23_BG
and CRF24_BG study sequences clustered mainly outside the cluster of
the respective CRF reference sequences precluding a reliable CRF as-
signment, but together they were monophyletic and were therefore
called CRF20–CRF23–CRF24_BG. Similarly, CRF19_cpx does not have
breakpoints in pol (subtype D) and env (subtype A), however, CRF19
identiﬁcation was consistent among subtyping tools, while clustering
inside the clade of the reference sequences, consequently CRF19_cpx
assignment was considered reliable.
Transmitted drug resistance was predicted using the 2009WHO list
(Bennett et al., 2009) (http://cpr.stanford.edu/cpr.cgi).
Co-receptor use prediction was with geno2pheno[co-receptor]: se-
quences with a false-positive rate (FPR) b5% are mainly CXCR4-using
(X4) and ≥20% are mainly CCR5-using (R5) variants. Therefore, we
classiﬁed V3 loop sequences with FPR ≥20% as R5 viruses, with FPR
≥5% and b20% as dual-tropic viruses and with FPR b5% as X4 viruses.
Our motivation for this classiﬁcation is as follows. Standard methods
for co-receptor prediction only classify HIV-1 variants into two catego-
ries, namely CCR5 and CXCR4-using viruses (Lengauer et al., 2007).
The group of CXCR4-using viruses comprises dual-tropic viruses and
X4 viruses. Dual-tropic viruses can use both the CCR5 and CXCR4 co-
receptors for cell entry, while X4 viruses can use CXCR4 but not CCR5.
The term dual/mixed is used by geno2pheno[co-receptor], referring to
either dual tropic viruses or to an unresolved mixture of viruses that
can use one or the other co-receptor, geno2pheno[co-receptor] cannot
discriminate between dual and mixed tropic viruses. If the V3 loop of
clinical samples are determined by single population-based Sanger se-
quences, the European guidelines on the clinical management of HIV-
1 tropism testing state that an FPR of geno2pheno[co-receptor] ≥20%
can be considered as evidence for an R5 virus, while an FPR b20%
would indicate a CXCRX4-using virus (Vandekerckhove et al., 2011).
As in this study we were interested in comparing X4 viruses and R5 vi-
ruses, we evaluated whether it is possible to differentiate between X4
and dual-tropic viruses given the geno2pheno[co-receptor] FPR. Previ-
ously, it has been shown for the PSSM method that dual-tropic viruses
mainly had a score between the scores of X4 viruses and R5 viruses
(Jensen et al., 2003).We showhere that the sameholds for the FPR gen-
erated by the geno2pheno[co-receptor] prediction tool. Supplementary
Fig. 2A shows the FPR distribution according to phenotypically con-
ﬁrmed R5 only, X4 only, or dual/mixed strains, for sequences that
were published at the LANL HIV sequence database between 2009 and
July 2013 (LANL_recent), while Supplementary Fig. 2B shows all se-
quences with phenotype information available in July 2013 (LANL_all).
Note that some of the sequences of the “LANL_all” data set were also
used for training geno2pheno[co-receptor]. It can be seen that the
FPRs of dual/mixed viruses are between the ones from R5 and X4 virus-
es for both data sets. The 25th percentile for R5 viruses was 20.7% and
17.8% for LANL_recent and LANL_all, respectively. This, in combination
with the fact that the European guidelines state that the HIV sequences
with a geno2pheno[co-receptor] FPR ≥20% are considered R5 viruses,
motivated us to utilize this threshold also in our study. Since themedian
FPR for dual/mixed viruses was 3.4% and 5.3% for the two data sets and
the median for X4 viruses was 0.3% and 0.5%, respectively, we chose 5%
as the FPR threshold for decidingwhether a virus is X4or not. This is also
supported by the German and Austrian guidelines for viral tropismdetermination stating that patients harboring HIV variants with
geno2pheno[co-receptor] FPRs below 5% should not be treated with
Maraviroc, while patients with an FPR ≥5% might still beneﬁt even if
the FPR is not above the R5 threshold (Eberle et al., 2014).
Evolutionary ﬁtness of pol sequences (PR and RT regions) was
estimated through a quantitative genotypic ﬁtness landscape for PR
and RT separately (Theys et al., 2012).
For transmission cluster analysis, pol sequences were pooled with
a) all other available Cuban sequences at IPK; b) the 30 most similar se-
quences to each of the study sequences retrieved from NCBI (http://
blast.ncbi.nlm.nih.gov/Blast.cgi); and c) all sequences retrieved from
the Los Alamos database (http://www.hiv.lanl.gov in December 2013)
by using the search term “Cuba” and duplicates were removed. Analysis
was done per subtype or CRF separately including also the respective
subtype reference sequences (from the Los Alamos database), outgroup
for subtype B was subtype D, and for all other subtypes and CRFs it was
subtype B. Sequences were aligned with MUSCLE, minimally edited
with Mega 5 (Edgar, 2004; Tamura et al., 2011), drug resistance related
positions (Bennett et al., 2009) were removed to avoid the effect of con-
vergent evolution (Lemey et al., 2005). An ML phylogenetic tree was
constructed using FastTree (Price et al., 2010) on 837 sequences for sub-
type B, 288 sequences for CRF19_cpx, and 204 for CRF20–CRF23–
CRF24_BG (average of 918 nucleotides) and transmission clusters were
identiﬁed with Cluster Picker (Ragonnet-Cronin et al., 2013) using as
cut-off genetic distances of 0.03, 0.045 and 0.06 with a bootstrap support
of 98% (Frentz et al., 2013; Leigh Brown et al., 2011).
2.4. Statistical Analysis
Parametric and non-parametric tests were used according to
Kolmogorov–Smirnov test for normality: Mann Whitney test, Spearman
correlation, Pearson correlation, Chi-square test for trend, Chi-square
test, One-way ANOVA with Holm–Sidak's multiple comparison post-test
and Kruskal–Wallis test with Dunn's multiple comparison post-test.
These were all two-tailed with a signiﬁcance level of 5% (GraphPad
Prism 5.0 software).
2.5. Data Mining
Bayesian network (BN) learning (using B-course adapted by Deforche
et al. (2006)) was used to describe and visualize conditional dependen-
cies between the multiple variables found signiﬁcant in univariate analy-
sis, discretizing continuous variables into quartiles. Dependencies are
represented qualitatively by a directed acyclic graph where each node
corresponds to a variable, and a direct arc between nodes represents a
direct inﬂuence. Robustness of the arcs was scored with a non-
parametric bootstrap test (100× replicates) (Friedman and WA,
1999) and only arcswithmore than 35% supportwere depicted. Included
variables were (Tables 1 and 2): AIDS-RP (AIDS-RP versus chronic-
AIDS + non-AIDS), non-AIDS (non-AIDS versus AIDS-RP + chronic-
AIDS), RANTES, IP-10, MCP-1, β2-microglobulin, neopterin, viral load at
sampling, heterosexual, anal contact, not always using condom, oral can-
didiasis, subtype CRF19_cpx, and not subtype B. Because of their strict as-
sociation with AIDS deﬁnition, collinearity and redundancy, CD4 levels at
HIV diagnosis, viral load at HIV diagnosis, CD4 levels at sampling and op-
portunistic infections were excluded to clarify other dependencies that
we were interested in.
3. Results
3.1. Descriptive Characteristics of Study Population
We recruited 95 treatment-naive HIV-1-infected patients, up to a
number of 52 in the AIDS-RP group, up to 21 in the non-AIDS group,
and up to 22 in the chronic-AIDS group. Study plasma samples and clini-
cal, epidemiological and laboratory data were collected (Tables 1 and 2).
Table 2
Clinical, immunological and virological markers at sampling for the three studied groups. Data are expressed asmedian values with interquartile ranges, or as proportion (%) with number
of patients between brackets. Statistical differences between groups were tested using Kruskal–Wallis or Chi-square test for trend. Results were considered signiﬁcant at p-value b0.05
(displayed in bold). N = number of patients. TDR (transmitted drug resistance): NRTI resistance mutations M41L, F116Y/T215S/K219Q, M41L/T215D and D67N/T215S/K219Q; NNRTI
resistance mutations twice K103N and PI resistance mutations N88DN and M46L.
*MIP-1β and IL-8 statistical graphs are depicted in Supplementary Fig. 6A and B, respectively.
Non-AIDS (N = 21) Chronic-AIDS (N = 22) AIDS-RP (N = 52) p value
Years elapsed from HIV seroconversion to sampling 1.75 (1.25–2.33) (21) 9.82 (7.97–12.06) (22) 1.40 (0.79–2.16) (52) –
Log VL at sampling (RNA copies/ml plasma) 3.7 (3.0–4.3) (N = 20) 4.7 (4.2–5.4) (N = 22) 4.7 (4.0–5.4) (N = 47) 0.0012
CD4 count at sampling (cells per μl blood) 501 (408–641) (N = 17) 212 (113–266) (N = 17) 189 (91–225) (N = 51) b0.0001
CD4% at sampling 23 (18–32) (N = 17) 12 (9–13) (N = 17) 11 (8–13) (N = 51) b0.0001
RANTES/CCL5 (pg/ml) 944 (719–1184) (N = 18) 1291 (932–1430) (N = 21) 1398 (1103–1630) (N = 47) 0.00060
MCP-1 (pg/ml) 0.0 (0.0–128.3) (N = 18) 127.1 (0.0–218.9) (N = 21) 122.70 (0.0–289.0) (N = 47) 0.046
MIP-1β (pg/ml) 0.0 (0.0–0.0) (N = 18) 0.0 (0.0–0.0) (N = 21) 0.0 (0.0–0.0) (N = 47) *
IP-10/CXCL10 (pg/ml) 0.0 (0.0–129.5) (N = 18) 0.0 (0.0–97.2) (N = 21) 79.43 (0.0–229.3) (N = 47) 0.047
MIG/CXCL9 (pg/ml) 0.0 (0.0–138.8) (N = 18) 139.1 (0.0–212.6) (N = 21) 125.8 (0.0–209.9) (N = 47) 0.15
IL-8 (pg/ml) 0.0 (0.0–0.0) (N = 18) 0.0 (0.0–0.0) (N = 21) 0.0 (0.0–0.0) (N = 47) *
FAS/APO (pg/ml) 750 (600–1197) (N = 18) 1094 (795–1154) (N = 21) 1030 (886–1381) (N = 48) 0.11
Neopterin (ng/ml) 1.0 (0.7–2.6) (N = 18) 2.1 (1.5–4.1) (N = 21) 2.7 (1.4–7.4) (N = 48) 0.020
β2-microglobulin (mg/ml) 1.1 (0.8–1.7) (N = 18) 1.91 (1.47–2.52) (N = 21) 1.92 (1.2–3.6) (N = 48) 0.0012
Hemoglobin (g/l) 131.5 (123.0–140.0) (N = 18) 125.0 (120.0–139.0) (N = 21) 130.0 (112.8–140.0) (N = 46) 0.95
Co-infections (proportion)
Oral candidiasis 4.8% (1/21) 0.0% (0/22) 23.1% (12/52) 0.013
Gonorrhea 28.6% (6/21) 9.1% (2/22) 17.3% (9/52) 0.40
HCV(1)/HBV(5) 9.5% (2/21) 9.1% (2/22) 3.9% (2/52) 0.96
Herpes simplex 23.8% (5/21) 45.5% (10/22) 15.4% (8/52) 0.18
Condyloma 19.1% (4/21) 13.6% (3/22) 7.7% (4/52) 0.16
Herpes zoster 4.8% (1/21) 22.7% (5/22) 13.5% (7/52) 0.52
Syphilis 4.8% (1/21) 18.2% (4/22) 7.7% (4/52) 0.98
Other co-morbidities (chronic non-infectious diseases)
Allergy 33.3% (7/21) 27.3% (6/22) 23.1% (12/52) 0.42
Hypertension 4.8% (1/21) 9.1% (2/22) 11.5% (6/52) 0.35
HIV subtypes (proportion)
Subtype B 42.1% (8/19) 42.9% (9/21) 17.3% (9/52) 0.016
Subtype C 0.0% (0/19) 4.8% (1/21) 9.6% (5/52) 0.13
CRF18_cpx 10.5% (2/19) 9.5% (2/21) 3.8% (2/52) 0.28
CRF19_cpx 0.0% (0/19) 0.0% (0/21) 17.3% (9/52) 0.012
CRF20,23,24_BG 36.8% (7/19) 23.8% (5/21) 32.7% (17/52) 0.91
TDR 10.5% (2/19) 4.8% (1/21) 9.6% (5/52) 0.95
Prediction of co-receptor use
X4 (FPR b 5%) 0.0% (0/13) 18.8% (3/16) 16.2% (6/37) 0.21
R5X4 (5% ≤ FPR b 20%) 30.8% (3/13) 31.3% (5/16) 37.8% (14/37) 0.59
R5 (FPR ≥ 20%) 70.6% (10/13) 50.0% (8/16) 45.95% (17/37) 0.07
247V. Kouri et al. / EBioMedicine 2 (2015) 244–254The patients were predominantly white young males from Havana
(median 33.0 years old at HIV diagnosis, 80% male) with no signiﬁcant
difference in age, gender and skin color distribution among groups
(Table 1).
For all groups, the median time between last negative and ﬁrst pos-
itive HIV test was similar: 16.0 months (IQR = 9.3–24.0 months), its
midpoint being the estimated seroconversion date. Median time be-
tween seroconversion and AIDS was 1.4 years in the AIDS-RP group
and 9.82 years in the chronic-AIDS group (Supplementary Fig. 1B). Sam-
pling was a median of 1.75 years after seroconversion for non-AIDS and
AIDS-RP groups (Table 2). At AIDS diagnosis, 16 patientswere identiﬁed
with opportunistic infections, 13 in the AIDS-RP group (25%) and 3 in
the chronic-AIDS group (14%). The most common opportunistic infec-
tion was Pneumocystis jirovecii (Table 1).
For 92 patients, at least partial pol and for 70 patients, both partial pol
and partial env regions sequences were available. Twenty six patients
were infected with subtype B, 6 with subtype C, 6 with CRF18_cpx, 9
with CRF19_cpx and 29 with CRF20–23–24_BG (Fig. 1A). The others
were infected with various other subtypes and URFs (Supplementary
Fig. 3).
3.2. Variables Associated With AIDS-RP
In univariate analysis with multiple comparison posttest correc-
tion, several signiﬁcant differences were observed (Tables 1–3 and
Supplementary Fig. 4A–I). As expected, at HIV diagnosis AIDS-RP pa-
tients had a signiﬁcantly higher median log viral load (4.8 log c/ml)(non-AIDS b1.7 log c/ml, chronic-AIDS 3.2 log c/mL); and signiﬁ-
cantly lower CD4 levels (276 cells/mm3) (non-AIDS 577 cells/μl,
chronic-AIDS 522 cells/μl) (Tables 1 & 3). At sampling, levels of
RANTES/CCL5, MCP-1, β2-microglobulin, neopterin, and viral load
were signiﬁcantly higher and CD4 count signiﬁcantly lower in
AIDS-RP group than in the non-AIDS group (Tables 2 & 3 and Sup-
plementary Fig. 4A–I); while AIDS-RP was not associated with a dif-
ferent proportion of transmitted drug resistance (Table 2) or a
higher proportion of X4-predicted viruses, irrespective of the cut-
off used (b5% or ≤20% FPR) (Table 2).
However, we found some surprising associations. Compared
to the combined non-AIDS and chronic-AIDS group, AIDS-RP were
signiﬁcantly more often heterosexual (49%), less prone to protect
themselves from superinfection or STIs (only 19.6% were always
using condoms after diagnosis), presented more often with oral
candidiasis (23.1%), were less frequently infected with subtype B
(17.3%) and more frequently with CRF19_cpx (17.3%) (Fig. 1A,
Tables 1–3). Strikingly, all 9 CRF19_cpx infected patients belonged
to the AIDS-RP group (Fig. 1A and Table 2). Another unusual associ-
ation was non-AIDS with anal sex. While we cannot exclude
underreporting of injecting drug use in our cohort, according to
the Cuban epidemiological information center, there are no reports
of IDU infected with HIV in the last years in Cuba.
Because of a complete overlap between some variables (e.g., all
CRF19_cpx were AIDS-RP), the assumptions of the classical regres-
sion model were violated by multicollinearity, prohibiting us to cal-
culate odds ratios using logistic regression. We therefore used a
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tient information signiﬁcantly associated with disease progression
groups in the univariate analysis. The AIDS-RP and non-AIDS groups
were displayed explicitly in the graph (Fig. 1B), by coding the groups'
binary (only two of the three groups are displayed, such thatchronic-AIDS is coded implicitly as not AIDS-RP and not non-AIDS).
This display allowed us to capture better the difference between
AIDS-RP and the other two groups, however we sacriﬁce clarity for
associations with chronic-AIDS. As expected, the BN approach re-
vealed that a lower viral load at sampling was associated with non-
Table 3
Multiple comparison posttest for the attributes signiﬁcantly associatedwith disease progression. Data are expressed asmedian valueswith interquartile ranges, or as proportion (%) with
number of patients between brackets. Statistical differences between AIDS-RP vs. non-AIDS and AIDS-RP vs. chronic-AIDS groups were tested using Dunn's multiple comparison test or
Chi-square test. Results were considered signiﬁcant at p-value b 0.05 (displayed in bold). N = number of patients.
Non-AIDS
(N = 21)
Chronic-AIDS
(N = 22)
AIDS-RP
(N = 52)
Multiple
comparison
posttest
AIDS-RP vs.
non-AIDS
Multiple
comparison
posttest
AIDS-RP vs.
chronic-AIDS
Multiple
comparison
posttest
Chronic-AIDS vs.
non-AIDS
Log VL at HIV diagnosis (RNA copies/ml plasma) b1.7
(b1.7–3.5)
(N = 12)
3.2 (b1.7–3.9)
(N = 8)
4.8 (4.1–5.4)
(N = 41)
b0.0001 0.0054 N0.99
CD4% at HIV diagnosis (%) 27 (19–35)
(N = 20)
24 (19–30)
(N = 21)
13 (10–19)
(N = 49)
b0.0001 b0.0001 N0.99
CD4 count at HIV diagnosis (cells per μl blood) 577
(441–815)
(N = 20)
522 (374–782)
(N = 22)
276 (152–386)
(N = 49)
b0.0001 b0.0001 N0.99
Log VL at sampling (RNA copies/ml plasma) 3.7 (3.0–4.3)
(N = 20)
4.7 (4.2–5.4)
(N = 22)
4.7 (4.0–5.4)
(N = 47)
0.0028 N0.99 0.0033
CD4 count at sampling (cells per μl blood) 501
(408–641)
(N = 17)
212 (113–266)
(N = 17)
189 (91–225)
(N = 51)
b0.0001 N0.99 0.0001
CD4% at sampling (%) 23 (18–32)
(N = 17)
12 (9–13)
(N = 17)
11 (8–13)
(N = 51)
b0.0001 N0.99 b0.0001
RANTES/CCL5 (pg/ml) 944
(719–1184)
(N = 18)
1291
(932–1430)
(N = 21)
1398 (1103–1630)
(N = 47)
0.0004 0.41 0.11
MCP-1 (pg/ml) 0.0
(0.0–128.3)
(N = 18)
127.1
(0.0–218.9)
(N = 21)
122.70 (0.0–289.0)
(N = 47)
0.047 0.66 0.83
IP-10/CXCL10 (pg/ml) 0.0
(0.0–129.5)
(N = 18)
0.0 (0.0–97.2)
(N = 21)
79.43 (0.0–229.3)
(N = 47)
0.22 0.093 N0.99
Neopterin (ng/ml) 1.0 (0.7–2.6)
(N = 18)
2.1 (1.5–4.1)
(N = 21)
2.7 (1.4–7.4)
(N = 48)
0.016 0.94 0.34
β2-microglobulin (mg/ml) 1.1 (0.8–1.7)
(N = 18)
1.91
(1.47–2.52)
(N = 21)
1.92 (1.2–3.6)
(N = 48)
0.0016 N0.99 0.0063
Anal sex (as reported by both males and
females of various sexual orientation)
80.0%
(16/20)
54.6% (12/22) 50.0% (25/50) 0.021 0.72 0.081
Always condom use after diagnosis 45.0% (9/20) 45.5% (10/22) 19.6% (10/51) 0.030 0.023 0.98
Sexual orientation
Heterosexual 20.0% (4/20) 36.4% (8/22) 49.0% (25/51) 0.025 0.32 0.24
Co-infections (proportion)
Oral candidiasis 4.8% (1/21) 0.0% (0/22) 23.1% (12/52) 0.064 0.014 0.30
HIV subtypes (proportion)
Subtype B 38.1% (8/21) 40.9% (9/22) 17.3% (9/52) 0.057 0.031 0.85
CRF19_cpx 0.0% (0/21) 0.0% (0/22) 17.3% (9/52) 0.042 0.037 –
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expression of RANTES, “not always using condoms” and not infected
with subtype B were associated with AIDS-RP (red in Fig. 1B). The
most robust association was with oral candidiasis (75% of boot-
straps) and with CRF19_cpx (62% of bootstraps). Moreover, the BN
approach demonstrated that CRF19_cpx, RANTES and oral candidia-
sis were also robustly interconnected (Fig. 1B).
3.3. Rapid Progression to AIDS is Associated With CRF19_cpx Subtype
One of the surprising ﬁndings from the BN analysis was the robust
association of CRF19_cpx with rapid progression. Our AIDS-RP patients
were infectedwith divergent CRF19_cpx strains and had thus not trans-
mitted a particular virulant variant among each other: none of them
clustered in a transmission cluster (Fig. 1C), while we did ﬁnd someFig. 1. CRF19_cpx is associated with rapid progression to AIDS. A) HIV subtype distribution am
to the disease progression rates (see Patients and methods). B) Variables found to be signiﬁc
(non-AIDS versus chronic-AIDS+ AIDS-RP) patients in univariate analysis were included in th
showing direct inﬂuences (arcs) between AIDS-RP, CRF19_cpx, oral candidiasis, higher RANTES
dependency was assessed with a non-parametric bootstrap (100× replicates). All arcs with boo
nistic dependencies. C) TheML phylogenetic tree for subtype CRF19_cpx (pol region) was const
and all other CRF19_cpx sequences retrieved from Los Alamos database (black), all other availa
(blue). One of the nine CRF19_cpx sequenceswas incomplete for pol region and not included in
from the Los Alamos HIV Sequence Database (http://www.hiv.lanl.gov/content/sequence/HIV/transmission clusters among the other clades (Supplementary Fig. 3).
There was not sufﬁcient information for the other CRF19_cpx patients
included in the transmission analysis to judge whether or not they
were fast progressors. CRF19_cpx is a complex recombinant HIV-1
virus consisting of subtype D sequence fragments (C-part of Gag, PR,
RT and nef), subtype A sequence fragments (N-part of Gag, Integrase,
Env) and subtype G fragments (Vif, Vpr, Vpu and C-terminal part of
Env) (Casado et al., 2005) (Fig. 1D).
3.4. CRF19_cpx-infected Patients Have High Viral Replication, High Immune
Activation and Frequent Co-infection
For all three groups, compared to subtype B and CRF20-23-24_BG as
the only other clades with a sufﬁcient number of sequences, CRF19
infected patients had signiﬁcantly higher viral load at HIV diagnosis,ong the three studied groups: non-AIDS, chronic-AIDS and AIDS-RP, classiﬁed according
antly associated with AIDS-RP (AIDS-RP versus non-AIDS + chronic-AIDS) or non-AIDS
e BNmodel. A central role for CRF19_cpx in rapid progression to AIDS was demonstrated,
, not always using condoms and not subtype B (red contours and arcs). The stability of the
tstrap over 35% are depicted in the network. All arcs with dashed lines represent antago-
ructed using FastTree. CRF19-cpx-infected AIDS-RP (red), CRF19_cpx reference sequences
ble CRF19_cpx sequences from IPK (black), and subtype B Los Alamos reference sequences
theML phylogenetic tree analysis. D)Mosaic structure of the CRF19_cpx genome as taken
CRFs/breakpoints.html#CRF19).
Fig. 2. Comparison of viral load, RANTES, estimated evolutionary ﬁtness, oral candidiasis and co-receptor use prediction among the most frequent HIV subtypes in our study (non-AIDS,
chronic-AIDS and AIDS-RP groups). A) Viral load (log copies/ml) at HIV diagnosis (One-way ANOVA, p= 0.0002, with Holm–Sidak'smultiple comparison test, *p b 0.05 and ***p b 0.001).
B) Viral load (log copies/ml) at sampling (One-wayANOVA, p=0.0043,with Holm–Sidak'smultiple comparison test, *p b 0.05). C) Evolutionaryﬁtness estimated from protease sequence
(log of ﬁtness value, logF) at sampling (Kruskal–Wallis test, p b 0.0001, with Dunn'smultiple comparison test, ****p b 0.0001). D) Proportionwith oral candidiasis at sampling (Chi-square
test, p = 0.0005). E) RANTES levels (pg/ml) at sampling (Kruskal–Wallis test, p = 0.038, with Dunn's multiple comparison test, *p b 0.05). F) Proportion of co-receptor use at sampling
(Chi-square test, p = 0.0051).
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CRF20–23–24_BG (Fig. 2A and B). CRF19 pol sequences at sampling
had a signiﬁcantly higher estimated in vivo ﬁtness score for protease(logF = 3.67) as compared to CRF20–23–24_BG (logF = 0.95)
(Fig. 2C), but not for reverse transcriptase (data not shown), and
this score was positively associated with log viral load at HIV diagnosis
Fig. 3. Comparison of viral load, RANTES, estimated evolutionary ﬁtness, oral candidiasis and co-receptor use between CRF19_cpx and all other HIV subtypes among AIDS-RP. A) Viral load
(log copies/ml) at HIV diagnosis (Mann Whitney test, *p b 0.05). B) Evolutionary ﬁtness estimated from protease sequence (log of ﬁtness landscape, logF) at sampling (Mann Whitney
test, ***p b 0.001). C) Viral load (log copies/ml) at sampling (MannWhitney test, p= 0.33). D) Proportionwith oral candidiasis at sampling (Chi-square test, p= 0.013). E) RANTES levels
(pg/ml) at sampling (MannWhitney test, *p b 0.05). F) Proportion of co-receptor use at sampling (Chi-square test, p = 0.014).
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had more frequently oral candidiasis (Fig. 2D) and higher RANTES levels
than subtype B or CRF20–23–24_BG infected patients (Fig. 2E). Consistent
with RANTES being a CCR5 ligand/competitor, CRF19 strains were more
often X4 viruses (b5% FPR cut-off) (Fig. 2F).
Strikingly, when considering only the AIDS-RP group and compared
to the other clades, CRF19_cpx infected patients had a signiﬁcantly
higher viral load at HIV diagnosis and in vivo estimated ﬁtness at sam-
pling (logVL = 6.23, and logF = 3.67, Fig. 3A and B), although viral
load at sampling was not signiﬁcantly different (Fig. 3C). In addition,
CRF19_cpx infected patients had more often oral candidiasis and had
higher RANTES levels (Fig. 3D and E), and CRF19 strains were alsomore often predicted as X4 (Fig. 3F). Together, these results suggest a
high evolutionary ﬁtness of CRF19_cpx.
4. Discussion
It has been speculated that inter-subtype recombination may give
rise to more pathogenic strains if genomic fragments from different
subtypes join together in a better replicating virus, but no direct evi-
dence for this scenario has so far been found. CRF19_cpx is a genetic
(Casado et al., 2005) form hitherto only reported in Cuba, but with evi-
denced central African ancestry (Thomson and Nájera, 2005; Casado
et al., 2005; Delatorre and Bello, 2013). Recently, clinicians in Cuba
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seroconversion) (Abrahantes et al., 2010). Here, we propose that this in-
crease is at least in part due to the spread of CRF19_cpx, whichwe found
exclusively associated with rapid progression to AIDS (within 3 years of
infection), whereas for other subtypes andCRFs, thedisease progression
was distributed as is generally seen in other parts of the world.
We set up an exploratory study in Cuba to investigate the association
of rapid progression with epidemiological, clinical, viral and immuno-
logical parameters, comparing three groups of patients. The ﬁrst two
groups were recruited prospectively who at sampling within 3 years
after seroconversion either were already diagnosed with AIDS (AIDS-
RP) or who were still AIDS-free (non-AIDS) and chronically infected
HIV-1 patients with AIDS recruited retrospectively and sampled at
AIDS diagnosis (chronic-AIDS). Bayesian network analysis showed
that rapid progression to AIDS in Cuba, being infected with CRF19_cpx,
having oral candidiasis, and having higher levels of RANTES are strongly
linked. CRF19_cpx was exclusively found among rapid progressors.
Compared to other patients in Cuba, CRF19_cpx infected patients have
a higher viral load at comparable times since infection, higher levels of
RANTES and are more frequently co-infected with oral candidiasis.
Additionally, the virus at sampling had higher estimated protease ﬁt-
ness and was predominantly using the CXCR4 co-receptor, potentially
explaining the rapid disease progression. Surprisingly however, even
when restricting the analysis to the 52 rapid progressors only, CRF19 in-
fection was signiﬁcantly associated with oral candidiasis, CXCR4 co-
receptor use prediction, higher RANTES levels, higher protease ﬁtness
at sampling and higher viral load at HIV diagnosis, whereas viral load
at sampling was not. Together the higher viral load and higher estimat-
ed in vivo ﬁtness of the viral protease suggest that CRF19 is an evolu-
tionary ﬁt virus. However, conﬁrmation by a phenotypic assay is still
warranted.
CRF19_cpx is composed of subtype D fragments (C-part of Gag, PR,
RT and nef), subtype A fragments (N-part of Gag, Integrase, Env) and
subtype G fragments (Vif, Vpr, Vpu and C-terminal part of Env)
(Casado et al., 2005). Several studies have reported the association of
HIV subtype D with faster disease progression and subtype A with
slower disease progression (Baeten et al., 2007; Kaleebu et al., 2002;
Kiwanuka et al., 2008). The probability of having an CXCR4-using
virus is higher in subtype D than in subtype A infections in non-AIDS
clinical status (Kaleebu et al., 2007), suggesting an earlier switch to
CXCR4 since dual tropism is not common in subtype D (Tscherning
et al., 1998). These ﬁndings cannot explain our observations since in
CRF19_cpx, the env region responsible for CXCR4 tropism is derived
from subtype A. The high viral load, the higher production of RANTES
(known to block CCR5 receptors) perhaps resulting from the high viral
load (Annunziato et al., 2000) and/or the co-infections (Huang and
Levitz, 2000), might be the reason for the high prevalence of CXCR4
use in this CRF19_cpx, and this may be the cause of the rapid disease
progression. This high viral load may be related to and potentially
caused by the high protease ﬁtness we observed in CRF19_cpx, and
thus could suggest a more important role of pol (subtype D portion),
and especially of protease, in disease progression, as compared to the
env region (subtype A portion) of CRF19_cpx.
Nevertheless, other subtype D genes in CRF19_cpx (gag and nef) not
investigated in this study might also be associated with increased viral
replication and in vivo pathogenesis. In HIV-1, Gag and Nef have been
documented to contain the highest CD8 epitope density and are more
frequently recognized by the immune system (Frahm et al., 2004). No-
tably, amino acid substitution T242N in the Gag p24 TW10 epitope is
highly associated with viral escape from the immune system (Leslie
et al., 2004). Subtype D-infected patients more often, and subtype A in-
fected patient less often display this T242N (Li et al., 2013). However,
T242N in subtype D reduces the viral replication and ﬁtness of the
virus (Martinez-Picado et al., 2006), while CRF19-infected patients
present a very high viral load. Another important protein is Nef, which
is responsible for the down-regulation of CD4 and HLA expression andup-regulation of immature HLA class II expression (Wang, 2013). Fur-
thermore, infection by HIV-1 with a truncated Nef contributes to low-
level viral replication and non-pathogenicity (Deacon et al., 1995).
However, subtype B Nef was found to be a better HLA class I down-
regulator in normal progressors than subtype D Nef. Yet, subtypes D
and A were similar in Nef-mediated CD4 and HLA class I down-
regulation (Mann et al., 2013).
Our study has several limitations. Even though the statistical link be-
tween fast progression and being infected with CRF19_cpx is very
strong, we only presented data on 9 such patients. An in depth study
on progression in patients infected with CRF19_cpx is needed. We
used two different genomic regions and a stringent method of
subtyping to increase our conﬁdence in subtyping, however, since we
did not have access to the full genome, we cannot exclude recombina-
tion in non-sequenced regions.We did not have sufﬁciently representa-
tive data to investigate the trend of CRF19_cpx incidence over the time
period that the increase in rapid progression was noted. However,
CRF19_cpx prevalence at HIV diagnosis at IPK, Cuba, increased over
the investigated time period (2007–2013) (data not shown). We were
also not able to investigate the host genotype, however we did conﬁrm
that there was no signiﬁcant difference in ethnic composition between
the three groups. Future studies should evaluate HLA and others host
genetic markers (CCR5) in new CRF19_cpx-infected patients. It would
also be interesting to test humoral and cellular immune responses in
new blood samples and to sequence more full-length CRF19_cpx
genomes.
We propose that an evolutionary very ﬁt CRF19_cpx together with
co-infections is linked to the increase of rapid progression to AIDS in
newly infected patients in Cuba. The robust and signiﬁcant associations
with a ﬁtter protease, more circulating virus, higher immune-activation
and CXCR4 co-receptor use suggest that CRF19_cpx may be a more
pathogenic virus.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ebiom.2015.01.015.
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